SELLAS Life Sciences Group, Inc. (SLS)
SLS Stock Price Chart
Explore SELLAS Life Sciences Group, Inc. interactive price chart. Choose custom timeframes to analyze SLS price movements and trends.
SLS Company Profile
Discover essential business fundamentals and corporate details for SELLAS Life Sciences Group, Inc. (SLS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Mar 2008
Employees
13.00
CEO
Angelos Stergiou
Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SLS Financial Timeline
Browse a chronological timeline of SELLAS Life Sciences Group, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.05.
Earnings released on 12 May 2026
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 19 Mar 2026
EPS came in at -$0.05 surpassing the estimated -$0.06 by +21.05%.
Earnings released on 12 Nov 2025
EPS came in at -$0.06 surpassing the estimated -$0.06 by +5.26%.
Earnings released on 12 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +16.00%.
Earnings released on 13 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.
Earnings released on 20 Mar 2025
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 13 Nov 2024
EPS came in at -$0.10 surpassing the estimated -$0.13 by +23.08%.
Earnings released on 13 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%.
Earnings released on 14 May 2024
EPS came in at -$0.21 falling short of the estimated -$0.16 by -31.25%.
Earnings released on 28 Mar 2024
EPS came in at -$0.25 falling short of the estimated $0.09 by -388.45%.
Earnings released on 9 Nov 2023
EPS came in at -$0.33 falling short of the estimated -$0.03 by -1.20k%.
Earnings released on 10 Aug 2023
EPS came in at -$0.31 surpassing the estimated -$0.35 by +11.43%.
Earnings released on 11 May 2023
EPS came in at -$0.47 falling short of the estimated -$0.29 by -62.07%.
Earnings released on 16 Mar 2023
EPS came in at -$0.43 falling short of the estimated $0.32 by -234.38%, while revenue for the quarter reached $1.00m .
Earnings released on 14 Nov 2022
EPS came in at -$0.34 surpassing the estimated -$0.39 by +12.82%.
Earnings released on 11 Aug 2022
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%.
Earnings released on 12 May 2022
EPS came in at -$1.05 falling short of the estimated -$0.38 by -176.32%, while revenue for the quarter reached $1.00m , meeting expectations.
Earnings released on 31 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.40 by -4.13%, while revenue for the quarter reached $7.60m .
Earnings released on 12 Nov 2021
EPS came in at -$0.45 falling short of the estimated -$0.38 by -18.42%.
Earnings released on 12 Aug 2021
EPS came in at -$0.30 surpassing the estimated -$0.39 by +23.08%, while revenue for the quarter reached $1.90m , meeting expectations.
SLS Stock Performance
Access detailed SLS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
